NuVox Pharma
NuvOx Therapeutics is a clinical-stage biotech company developing a best-in-class oxygen therapeutic, NanO₂™. NanO₂ is designed to reverse hypoxia, a leading cause of death and morbidity, and has clinical programs in stroke, oncology, and respiratory distress. The company has compelling results from its phase IIa stroke and oncology trials.
Company Ownership:
Socially Disadvantaged
Contact Name:
Evan Unger
Contact Email:
Website:
https://www.nuvoxpharma.com/
City, State – Congressional District:
Tucson,
AZ
–
7
Technology:
Drug
Funding:
Cancer (NCI),
Child Health (NICHD),
Heart, Lung, and Blood (NHLBI),
Neurological Disorders and Stroke (NINDS)
NIH Projects:
NIH RePorter for
NuVox Pharma
Sponsored Event(s):
Landmark Investing for Cures | 2022
,
Biotech Showcase | 2025
